Initial-onset acute and chronic recurrent stages are two distinctive courses of VogtKoyanagi-Harada disease
Author
dc.contributor.author
Urzúa Salinas, Cristhian
Author
dc.contributor.author
Herbort, Carl
Author
dc.contributor.author
Valenzuela, Rodrigo A.
Author
dc.contributor.author
Abu El-Asrar, Ahmed M.
Author
dc.contributor.author
Arellanes García, Lourdes
Author
dc.contributor.author
Schlaen, Ariel
Author
dc.contributor.author
Yamamoto, Joyce
Author
dc.contributor.author
Pavesio, Carlos
Admission date
dc.date.accessioned
2021-01-27T19:43:34Z
Available date
dc.date.available
2021-01-27T19:43:34Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Journal of Ophthalmic Inflammation and Infection (2020) 10:23
es_ES
Identifier
dc.identifier.other
10.1186/s12348-020-00214-2
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/178368
Abstract
dc.description.abstract
Purpose: To describe distinctive stages of Vogt-Koyanagi-Harada (VKH) disease: initial-onset acute versus chronic
recurrent disease.
Methods: A comprehensive literature review regarding stages and clinical presentations of VKH disease was
conducted.
Results: Despite a list of signs that has been described as characteristic features of early or late phases of VKH
disease, the current classification -developed by an international committee and published in 2001- does not
consider a distinction regarding the time from onset of disease symptoms, and specific findings observed at certain
time point from the symptoms presentation and outcomes related to the stage of VKH disease. In that sense,
chronic recurrent VKH disease is more refractory to treatment and is associated with a higher rate of complications.
Accordingly, this subset of VKH patients has poorer functional and anatomical outcomes than patients with an
initial-onset acute disease.
Conclusions: An early clear distinction of VKH phenotype [Initial-onset acute versus chronic recurrent disease]
should be considered in each clinical scenario, evaluating the delay in diagnosis and the clinical presentation, since
it may help clinicians to perform a correct disease prognosis categorization and thus to make treatment decisions
in terms of potential refractoriness or expected clinical outcomes.
es_ES
Patrocinador
dc.description.sponsorship
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
CONICYT FONDEF
IT17/0087